共 42 条
- [21] Final results of a first-in-human phase I dose escalation trial of daily oral zelenirstat, a n-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomasJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Sangha, Randeep S.Jamal, RahimaSpratlin, JenniferKuruvilla, JohnSehn, Laurie HelenWeickert, MichaelBerthiaume, Luc G.Mackey, John Robert
- [22] Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Nakajima, Takako EguchiKuboki, YasutoshiFukahori, MasaruShimazu, YutakaKondo, ShunsukeKatsuya, YukiIkeda, MasafumiSatake, TomoyukiKagehara, HideakiAkaike, TakenoriSingh, Aman P.Atkuri, KondalaPop-Damkov, PetarTamada, KojiKoyama, Takafumi
- [23] YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I studyANNALS OF ONCOLOGY, 2024, 35 : S485 - S485Zhao, H.Ma, Y.Meng, X.Wu, L.Fan, Y.Zheng, Y.Liu, Z.Ji, Y.Lv, D.Luo, S.Sommerhalder, D.Fu, S.Huang, Y.Yang, Y.Fang, W.Zhao, Y.Wang, Y.Chin, S.Xue, T.Zhang, L.
- [24] STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Pinto, Navin R.Albert, Catherine MichelleTaylor, MalloryWilson, AshleyRawlings-Rhea, StephanieHuang, WenjunSeidel, KristyNarayanaswany, PrabhaWu, VickyBrown, ChristopherNicholas, A.Orentas, Vitanza RimasGardner, Rebecca AliceJensen, Michael C.Park, Julie R.
- [25] A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Shankar, SadhnaSpira, Alexander I.Strauss, JamesLiu, LiqinLa Motte-Mohs, RossWu, TonyJohnson, SydBonvini, EzioMoore, Paul A.Wigginton, Jon M.Vasselli, Jim
- [26] A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Wermke, MartinFelip, EnriquetaGambardella, ValentinaKuboki, YasutoshiMorgensztern, DanielHamed, Zohra Oum'Geng, JunxianStudeny, MatusOwonikoko, Taofeek K.
- [27] A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Desantes, KennethMaris, John M.McDowell, KimberlyMackall, CrystalShankar, SadhnaVasselli, JimChen, FrancineLoo, DerykMoore, Paul A.Wigginton, Jon M.Sonde, Paul M.
- [28] Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Jang, SekwonPowderly, John D.Spira, Alexander I.Bakkacha, OuiamLoo, DerykBohac, Gerry C.Sharma, Manish
- [29] Updated data from a phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumors: Focus on extrapulmonary neuroendocrine carcinomas (epNECs)JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 227 - 227Capdevila, J.Gambardella, VKuboki, Y.Alese, O. B.Morgensztern, D.Sayehli, C.Sanmamed, M. F.Arriola, E.Wolf, J.Owonikoko, T.Studeny, M.Wermke, M.
- [30] A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen x CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple MyelomaJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3576 - +D'Souza, AnitaShah, NinaRodriguez, CesarVoorhees, Peter M.Weisel, KatjaBueno, Orlando F.Pothacamury, Rajvineeth K.Freise, Kevin J.Yue, SusanRoss, Jeremy A.Polepally, Akshanth R.Talati, ChetasiLee, ShaneJin, ZiyiBuelow, BenVij, RaviKumar, Shaji